Generic Name and Formulations:
Patiromer 8.4g, 16.8g, 25.2g; per pkt; pwd for oral susp.
Indications for VELTASSA:
Limitations Of use:
Not for emergency treatment for life-threatening hyperkalemia due to its delayed onset of action.
Give at least 3hrs before or 3hrs after other oral medications. Take without regard to food; mix with water. Initially 8.4g once daily. Adjust dose in 8.4g increments as needed at ≥1-week intervals to obtain desired serum potassium target range; max 25.2g/day.
Binding to other oral medications.
Avoid in severe constipation, bowel obstruction or impaction, abnormal post-op bowel motility disorders. Monitor serum potassium, magnesium. Consider magnesium supplementation if low serum levels develop.
May reduce absorption and efficacy of other oral medications; separate dosing by at least 3hrs.
Constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort, flatulence.
Single-use packets (8.4g)—4, 30; (16.8g, 25.2g)—30
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness